Kiniksa Pharmaceuticals International
KNSA· Manufacturing· Fiscal year ends in December
Sanj K. Patel is the CEO of Kiniksa Pharmaceuticals International and was paid $10.8M in FY2025 (Dec), up 51%.
Executives5
See all- 1Sanj K. PatelChief Executive Officer and Chairman of the BoardFY2025
- 2Ross MoatExecutive Vice President and Chief Commercial OfficerFY2025
- 3John F. Paolini, M.D.Executive Vice President and Chief Medical OfficerFY2025
- 4Eben TessariExecutive Vice President and Chief Operating OfficerFY2025
- 5Mark RagosaSenior Vice President and Chief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allKiniksa Pharmaceuticals International paid its 5 named executives $24.8M in total in FY2025 (Dec). CEO Sanj K. Patel was paid $10.8M of that.
| Name | |||
|---|---|---|---|
| Sanj K. PatelChief Executive Officer and Chairman of the Board | |||
| Ross MoatExecutive Vice President and Chief Commercial Officer | |||
| John F. Paolini, M.D.Executive Vice President and Chief Medical Officer | |||
| Eben TessariExecutive Vice President and Chief Operating Officer | |||
| Mark RagosaSenior Vice President and Chief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers20
See allThe FY2025 (Dec) proxy of Kiniksa Pharmaceuticals International names 20 peer companies for pay. Among Kiniksa Pharmaceuticals International and these peers, CEO pay was 4th highest of 10 and total shareholder return was the highest of 10.
4th highest of 10in Kiniksa Pharmaceuticals International and its pay peers, FY2025 (Dec) by CEO pay:
1st highest of 10in Kiniksa Pharmaceuticals International and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board4
See all- Felix J. Baker, Ph.D.Lead independent director · 9 yr on the boardIndependentNominating and Corporate Governance, Science and Research—Paid as an executive
- Stephen R. Biggar, Ph.D.Director · 9 yr on the boardIndependentNominating and Corporate Governance (Chair), Science and Research—Paid as an executive
- Thomas R. MalleyDirector · 8 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive
- Tracey L. McCainDirector · 6 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2024).
Activity
- PayDEF 14A
- PayDEF 14A
- PayDEF 14A
- PayDEF 14A
- PayDEF 14A
- PayKiniksa Pharmaceuticals International CEO pay rose 35% to $7.1M. The stock rose 13% in FY2024 (Dec).DEF 14A
- PayDEF 14A
- PayKiniksa Pharmaceuticals International CFO pay rose 25% to $2.2M. The stock rose 13% in FY2024 (Dec).DEF 14A
- PayDEF 14A
- PayKiniksa Pharmaceuticals International COO pay rose 34% to $2.4M. The stock rose 13% in FY2024 (Dec).DEF 14A
- PayKiniksa Pharmaceuticals International CEO pay fell 13% to $5.3M. The stock rose 17% in FY2023 (Dec).DEF 14A
Filings6
See all| Proxy statement | DEF 14A | Apr 16, 2026 | FY2025 |
| Annual report | 10-K | Feb 24, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 21, 2025 | FY2024 |
| Annual report | 10-K | Feb 25, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 23, 2024 | FY2023 |
| Annual report | 10-K | Feb 28, 2024 | FY2023 |
